Citations

Clear

3057 citation(s) found for "Cd, Johnson".

EP4.5 Safety of Intra-articular Corticosteroid Hip Injections: A Retrospective Analysis of Avascular Necrosis Development
Simon, Karissa, Scott, Parker, Sellon, Jacob L. , Johnson, Adam, Clark, Sean C. , Pan, Xuankang , Boettcher, Brennan J. , Johnson, Adam, Hevesi, Mario

Mayo Clinic

Journal of Hip Preservation Surgery | April 2, 2025 | Volume: 12 | Issue: Supplement_1 | Pages: i80-i80

10.1093/jhps/hnaf011.258 Get It

Abstract Background: Intra-articular corticosteroid injections (ICSI) have been shown to be an effective symptomatic non-operative treatment for hip osteoarthritis (OA) and other joint-related pain. There has been recent dispute over the true risk of complications from ICSI specifically when injected into the hip. Avascular necrosis (AVN) of the femoral head has been reported to occur in up to 30.5% of patients after undergoing hip ICSI, and up to 50.6% of patients experiencing osteoarthritis progression in as little as 3 months following injection. Purpose: To analyze the current protocol of hip ICSIs performed by two fellowship-trained non-operative sports medicine physicians and assess the rate of femoral head avascular necrosis. We hypothesized that the rate of AVN will be less than what has been recently reported in the literature. Study Design: Retrospective chart review Methods: Patients that underwent at least one intra-articular corticosteroid hip injection by two fellowship trained non-operative sports medicine physicians at this institution were identified using an institutional database. Exclusion criteria included injections with contrast dye used for imaging, injections that administered orthobiologics to the intra-articular, and non-intra-articular injections. Procedure notes were reviewed for anesthetic and steroid type, dosage, and needle size. Each chart was screened for demographic information, post-injection infections, AVN diagnosis, and subsequent hip replacement. 10 patients were identified with an AVN diagnosis. Their MRNs were sent to a board-certified radiologist at the same medical institution. The radiologist was blinded to the patient’s chart and instructed to identify the first radiograph with evidence of AVN. Patients were excluded if the reviewer did not agree with the diagnosis as it appeared in the medical chart or the AVN developed post-traumatically. Results: 449 patients, 530 hips, underwent 1.8 ± 1.4 ICSIs and 16.3% underwent THA at an average of 2.2 ± 2.3 years following their first injection. Of the 530 hips that underwent ICSI, only 1 hip demonstrated findings of AVN on radiographs following the first injection, and this patient had been taking oral prednisone for over 20 years. Conclusions: Intra-articular corticosteroid injections are a relatively safe symptomatic treatment option for hip pain secondary to both OA and non-OA pathology to be considered when other non-operative treatment options have failed. While the use of steroids comes with an inherent risk of osteonecrosis and cartilage damage, these results demonstrate that, when performed properly with ultrasound guidance and sterile technique, the risk of femoral head avascular necrosis is minimal.
MRI Findings of Facet Joint Septic Arthritis
Weger, Kendal L. , Mark, Ian T. , Gallagher, Clare, Johnson-Tesch, Ben A. , Mark, Ian , Gallagher, Clare, Hoxworth, Joseph M. , Tande, Aaron J. , Carr, Carrie M.

Mayo Clinic

Clinical Neuroimaging | April 1, 2025 | Volume: 2 | Issue: 1 | Pages: No page available

10.1002/neo2.70015 Get It

ABSTRACT Background Facet Joint Septic Arthritis (FJSA) is an infection of the spinal facet joints, for which previously described imaging findings are non‐specific. We present MRI findings of 20 patients who underwent facet biopsy for possible FJSA. Materials and Methods An internal database was reviewed for cases who underwent image‐guided spinal facet biopsy for possible infection and had pre‐biopsy contrast‐enhanced MRI. Cases were categorized as biopsy FJSA positive or negative and MRI was reviewed for synovitis, bone marrow enhancement, epidural phlegmon/abscess, and paraspinal muscle enhancement. The MRI findings were considered extensive if the involvement of the posterior paraspinal muscles spanned at least two vertebral bodies in the craniocaudal direction and at least half the length of the muscles in the anterior‐posterior direction. Results Twenty patients were included. Nine patients were FJSA positive, all of whom had synovitis, bone marrow enhancement of the facet joints, and epidural phlegmon. No patients had epidural abscess, but five patients had a paraspinal abscess. All nine patients demonstrated extensive paraspinal muscular enhancement. Eleven biopsy cases that were negative for FSJA were included. Their MRI findings demonstrated all with synovitis, six with bone marrow enhancement of the facet joints, six with epidural phlegmon, none with epidural abscess, and none with paraspinal abscess. Only one FJSA negative case had extensive paraspinal muscle enhancement. Conclusion The MRI appearance of FJSA has rarely been described in the literature; however, the diagnosis has a significant clinical impact. Facet enhancement with florid posterior paraspinal muscle enhancement should raise suspicion for FSJA.
Reliability and Validity of Measuring Shoulder Internal and External Rotation Strength in Volleyball Specific Positions
Loepfe, John G., Nagelli, Christopher V. , Cherny, Chad E., Johnson, Andrew , Larson, Dirk R. , Johnson, Andrew J, Tagliero, Adam J. , Johnson, Andrew J., Johnson, Andrew

Mayo Clinic

International Journal of Sports Physical Therapy | March 31, 2025 | Volume: 20 | Issue: 4 | Pages: No page available

10.26603/001c.132170 | PMID 40182905 Get It

Background Overhead athletes are susceptible to shoulder injuries, among which rotator cuff injuries are common and often directly associated with muscle weakness. Therefore, valid and reliable measures of rotator cuff strength at sport specific positions may be a vital part of sports physical therapy practice. Purpose: The current study aimed to determine the inter- and intra-tester reliability of measuring shoulder internal rotation (IR) and external rotation (ER) strength at a novel testing position, 130° of abduction and compared to the 90°/90° position. A secondary aim was to assess concurrent validity between measurements taken with the Humac® Norm™ Isokinetic Dynamometer (IKD) and Microfet® 2 hand-held dynamometer (HHD). Study Design Inter-Rater and Intra-Rater Reliability and Criterion Validity Methods Twenty-five (n=25) healthy participants were recruited for this study. Exclusion criteria included prior shoulder surgery, shoulder injury within the last three months, and contraindications to exercise according to ACSM guidelines. Participants performed maximal isometric shoulder external and internal rotation strength testing at both 90° and 130° of shoulder abduction. On the first day, participants were tested on the IKD at both positions, followed by each tester using the HHD. Participants returned 7-14 days later for repeat testing using the HHD only. ICC values were calculated for each rater, instrument, and testing position. Bland-Altman plots were created to establish limits of agreement. Minimal detectable change values were calculated. Results Inter- and intra-rater reliability for testing isometric strength using a hand-held dynamometer was good to excellent for both shoulder positions with ICC values consistently above 0.8. Concurrent validity between the HHD and IKD was poor to moderate with ICC values ranging from 0.1-0.4. However, Bland-Altman plots demonstrated that the difference in strength measures was within the limits of agreement. Conclusion Shoulder IR and ER strength testing at 130° of abduction shows strong inter-rater and intra-rater reliability for measurement in sport specific positions. Level of Evidence Level 3
Proton dose calculation with transformer: Transforming spot map to dose
Tang, Xueyan , Tseung, H. Wan Chan, Johnson, Jed E., Moseley, D.J., Tseung, Hok Wan Chan, Moseley, Doug J, Qian, Jing , Pepin, Mark D., Routman, David M. , Qian, Jing

Mayo Clinic

Medical Physics | March 31, 2025 | Volume: 52 | Issue: 6 | Pages: 4941-4952

10.1002/mp.17794 | PMID 40156258 Get It

Abstract Background Conventional proton dose calculation methods are either time‐ and resource‐intensive, like Monte Carlo (MC) simulations, or they sacrifice accuracy, as seen with analytical methods. This trade‐off between computational efficiency and accuracy highlights the need for improved dose calculation approaches in clinical settings. Purpose This study aims to develop a deep‐learning‐based model that calculates dose‐to‐water ( D W ) and dose‐to‐medium ( D M ) using patient anatomy and proton spot map (PSM), achieving approaching MC‐level accuracy with significantly reduced computation time. Additionally, the study seeks to generalize the model to different treatment sites using transfer learning. Methods A SwinUNetr model was developed using 259 four‐field prostate proton stereotactic body radiation therapy (SBRT) plans to calculate patient‐specific D W and D M distributions from CT and projected PSM (PPSM). The PPSM was created by projecting PSM into the CT scans using spot coordinates, stopping power ratio, beam divergence, and water‐equivalent thickness. Fine‐tuning was then performed for the central nervous system (CNS) site using 84 CNS plans. The model's accuracy was evaluated against MC simulation benchmarks using mean absolute error (MAE), gamma analysis (2% local dose difference, 2‐mm distance‐to‐agreement, 10% low dose threshold), and relevant clinical indices on the test dataset. Results The trained model achieved a single‐field dose calculation time of 0.07 s on a Nvidia‐A100 GPU, over 100 times faster than MC simulators. For the prostate site, the best‐performing model showed an average MAE of 0.26 ± 0.17 Gy and a gamma index of 92.2% ± 3.1% in dose regions above 10% of the maximum dose for D W calculations, and an MAE of 0.30 ± 0.19 Gy with a gamma index of 89.7% ± 3.9% for D M calculations. After transfer learning for CNS plans, the model achieved an MAE of 0.49 ± 0.24 Gy and a gamma index of 90.1% ± 2.7% for D W computations, and an MAE of 0.47 ± 0.25 Gy with a gamma index of 85.4% ± 7.1% for D M computations. Conclusions The SwinUNetr model provides an efficient and accurate method for computing dose distributions in proton therapy. It also opens the possibility of reverse‐engineering PSM from D W , potentially speeding up treatment planning while maintaining accuracy.
Prevalence of symptomatic toxicities for novel therapies in adult oncology trials: a scoping review
King, Amanda , Vasilj, Tamara , Cooper, Diane, Vera, Elizabeth , Berhanu, Sefanit, Johnson, Morgan , Locke, Ciara, McIver, Bennett , Basch, Ethan, Cappeleri, Joseph, Dueck, Amylou, Jones, Lee , Minasian, Lori M. , Mendoza, Tito R. , Dueck, Amylou C. , Cappelleri, Joseph C. , Dueck, A. C. , King, Amanda L , Basch, Ethan , Cappelleri, Joseph C , Gilbert, Mark R , Jones, Lee , Li, Yuelin , Reeve, Bryce B. , Armstrong, Terri S , Mendoza, Tito , Johnson, Morgan , Li, Yuelin , Armstrong, Terri S.

Mayo Clinic

JNCI Cancer Spectrum | March 31, 2025 | Volume: 9 | Issue: 3 | Pages: No page available

10.1093/jncics/pkaf036 | PMID 40152251 Get It

Abstract Background Patients’ self-report of their symptoms can provide important data for the evaluation of treatment benefit and tolerability of oncology drugs. Contemporary treatment approaches, including immunotherapy and molecular targeted therapies, have unique toxicities based on their novel mechanisms of action. This scoping review aimed to summarize evidence from existing reviews and clinical practice guidelines to examine the type and prevalence of toxicities including symptomatic adverse events (sympAEs) for adult cancer patients to inform clinical care and therapeutic trials. Methods A systematic search of PubMed, Web of Science, and Embase was performed using predefined eligibility criteria. Thirty-one literature reviews and 3 clinical practice guidelines met inclusion criteria and were selected for review and data abstraction. Results Findings from this scoping review demonstrated several leading sympAEs that were reported across immunotherapy and targeted therapy drugs, including fatigue, diarrhea, and rash. In addition to these more prevalent sympAEs, there were some less frequently reported class-specific sympAEs, which had potential for significant harm or disability to the patient if not properly identified and treated. Many studies reported toxicities as AEs or syndromes solely using data reported by clinicians without additional self-report from patients. Conclusion We identified several core sympAEs experienced by patients participating in oncology trials using immunotherapy and targeted therapy agents, which has implications for future trial design and drug labeling. Future cancer trials should assess patient-reported sympAEs based on the identified drug mechanism to inform the tolerability of these newer agents and enhance patient safety during trial participation and clinical care.
Practical Anemia Bundle and Hemoglobin Recovery in Critical Illness
Hanson, Andrew C. , Fortune, Emma , Flaby, Gerald W., Schulte, Phillip J. , Hazelton, Valerie M., Beam, William B. , Anderson, Brenda, Karon, Brad S. , Kor, Daryl J. , Johnson, Matthew L. , Beam, W Brian, Charnin, Jonathan E. , Anderson, Brenda K, Karon, Brad, Warner, Matthew A. , Go, Ronald S. , Cheville, Andrea , Gajic, Ognjen

Mayo Clinic

JAMA Network Open | March 28, 2025 | Volume: 8 | Issue: 3 | Pages: e252353

10.1001/jamanetworkopen.2025.2353 | PMID 40152861 Get It

Importance Anemia is a common complication of surgery and acute illness that is associated with adverse clinical outcomes. The role of anemia prevention and treatment strategies in this setting remains unclear. Objective To evaluate the effect of a multifaceted anemia management bundle vs standard care on posthospitalization hemoglobin recovery and multidimensional functional outcomes in survivors of acute illness. Design, Setting, and Participants This parallel group randomized clinical trial, known as the Practical Anemia Bundle for Sustained Blood Recovery, was conducted at postsurgical and medical intensive care units at a large US medical center. Critically ill patients (aged ≥18 years) with moderate to severe anemia (hemoglobin concentration <10 g/dL) were enrolled between March 2022 and November 2023. Participants were randomly assigned 1:1 to the intervention or standard care group. Intention-to-treat analyses were performed between July 2024 and January 2025. Intervention The intervention bundle was delivered throughout the duration of hospitalization and included optimized phlebotomy practices, clinical decision support, and pharmacological anemia treatment with intravenous iron. Main Outcomes and Measures The primary outcome was the mean difference in hemoglobin concentration at 1 month after hospital discharge. Results A total of 100 patients (median [IQR] age, 68 [61-72] years; 57 men [57.0%]; 65 [65.0%] with postsurgical admission to the intensive care unit) were enrolled during acute illness. Forty-nine patients (49.0%) were assigned to receive the intervention, and 51 (51.0%) were assigned to receive standard care. Hemoglobin concentration at 1 month after discharge was greater in patients receiving the intervention vs standard care (median [IQR], 12.2 [11.8-13.0] g/dL vs 11.5 [10.2-12.6] g/dL; adjusted mean difference, 0.69 [95% CI, 0.13-1.20] g/dL; P = .02). Conclusions and Relevance This randomized clinical trial found that a multifaceted anemia prevention and treatment bundle was feasible, was well tolerated, and improved posthospitalization hemoglobin concentrations up to 3 months in critically ill adults. These findings can inform the design of future trials. Trial Registration ClinicalTrials.gov Identifier: NCT05167734
Selective Elimination of Breast Surgery for Invasive Breast Cancer
Kuerer, Henry M. , Valero, V, Krishnamurthy, Savitri, Diego, Emilia J. , Lin, Heather , Shen, Yu , Mitchell, Melissa P. , Yang, Wei , Group, Exceptional Responders Study, Moseley, Tanya W. , Leung, Jessica WT, Huang, Monica L. , Parra, Raquel FD van la, Teshome, Mediget , Hwang, Rosa F. , Miggins, Makesha, Piotrowski, Matthew J., Refinetti, Ana P, Ehlers, Richard A., Mouabbi, Jason , Colen, Jessica Suarez, Loveland‐Jones, Catherine, Lesnikowski, Beth Ann, Samiian, Laila, Chong, Clayton, Black, Dalliah M. , Desyder, Sarah M, Nguyen, Tuyen , Smith, Benjamin D. , Krishnamurthy, Savitri , Johnson, Helen Margaret , Lucci, Anthony , Shaitelman, Simona Flora , Boughey, Judy C. , White, Richard L., Hunt, Kelly K. , Rauch, Gaiane M. , Group, Exceptional Responders Study, Candelaria, Rosalind P. , Adrada, Beatriz E. , Arribas, Elsa , Ramirez, David Luis , Sun, Susie X.

Mayo Clinic

JAMA Oncology | March 28, 2025 | Volume: 11 | Issue: 5 | Pages: 529

10.1001/jamaoncol.2025.0207 | PMID 40152443 Get It

Importance Neoadjuvant systemic therapy (NST) has been associated with pathologic complete response (pCR) in up to 60% of breast cancers (BCs). The findings of this trial question the necessity of surgery. Objective To report preplanned 5-year efficacy outcomes evaluating radiotherapy alone without breast surgery in patients selected with image-guided vacuum assisted biopsy (VAB). Design, Setting, and Participants This single-arm, prospective, phase 2 nonrandomized clinical trial was conducted at 7 US medical centers and included women 40 years or older with cT1-2N0-1M0 ERBB2 -positive (formerly HER2 -positive) or triple-negative invasive BC who showed residual breast lesions after NST of less than 2 cm on imaging. Enrollment was from March 6, 2017, to November 9, 2021. Data analysis was from October to December 2024. Intervention Image-guided VAB of the tumor bed (9G with a minimum of 12 cores) was performed after standard NST. Patients with clinically node-negative disease at diagnosis and no residual cancer in the breast on post-NST VAB underwent whole-breast radiotherapy with a boost without breast or axillary surgery. Patients with initial documented nodal disease and a breast pCR on VAB underwent targeted axillary dissection, while those with residual cancer when undergoing VAB had standard breast and axillary surgery. Patients were monitored with physical examinations and mammography every 6 months. Main Outcome Measures The primary outcome was ipsilateral breast tumor recurrence. Results Fifty patients (median [IQR] age, 62 [55-77] years) were enrolled and underwent post-NST VAB. Twenty-nine (58%) and 21 (42%) patients had ERBB2 -positive and triple-negative invasive BC, respectively. Breast pCR on VAB was identified in 31 patients (62%; 95% CI, 47.2%-75.34%), and axillary pCR was identified among all 8 patients with initial nodal metastases and breast pCR on VAB who underwent targeted axillary dissection. At a median follow-up of 55.4 (IQR, 44.0-63.5) months, the ipsilateral breast tumor recurrence rate was 0%, and disease-free and overall survival rates were 100% for patients without breast surgery. Conclusions and Relevance The results of this nonrandomized clinical trial that reported preplanned 5-year outcomes suggest that omission of breast surgery in select patients after NST may be feasible, with no recurrences seen. More confirmatory studies are necessary before this new approach alters surgical practice. Trial Registration ClinicalTrials.gov Identifier: NCT02945579
Recovery Potential in Patients After Cardiac Arrest Who Die After Limitations or Withdrawal of Life Support
Elmer, Jonathan, Ratay, Cecelia , Steinberg, Alexis , DiFiore-Sprouse, Sara, Case, Nicholas , De‐Arteaga, Maria , Cariou, Alain, Rossetti, Andrea O. , Doshi, Ankur , Molyneaux, Bradley J. , Maciel, Carolina B. , Leithner, Christoph , Sandroni, Claudio , Seder, David B., Taccone, Fabio Silvio, Soar, Jasmeet , Lascarrou, Jean-Baptiste, Nolan, Jerry P. , Hirsch, Karen G. , Berg, Katherine M. , Moseby‐Knappe, Marion , Skrifvars, Markus B., Kurz, Michael C. , Chae, Min Jung Kathy, Kurtz, Pedro, Geocadin, Romergryko G. , Agarwal, Sachin , May, Teresa , Olasveengen, Theresa M. , Group, Optimizing Recovery Prediction After Cardiac Arrest (ORCA) Study, Cariou, Alain , Greer, David M., Seder, David B., Naito, Hiromichi, Nolan, Jerry P., Elmer, Jonathan, Moseby-Knappe, Marion, Skrifvars, Markus B., Donnino, Michael W. , Sekhon, Mypinder, Coppler, Patrick J., Kurtz, Pedro, Seder, David B. , Lascarrou, Jean-Baptiste , Elmer, Jonathan, Coppler, Patrick J. , Fischhoff, Baruch , Rabinstein, Alejandro A. , Dezfulian, Cameron , Hsu, Cindy H. , Greer, David M. , Seder, David B., Guyette, Francis Xavier , Naito, Hiromichi , Skrifvars, Markus B., Chae, Minjung Kathy , Sekhon, Mypinder S. , Johnson, Nicholas James , Kurtz, Pedro, Callaway, Clifton W. , Group, Optimizing Recovery Prediction After Cardiac Arrest (ORCA) Study, Greer, David M., Seder, David B., Naito, Hiromichi, Nolan, Jerry P., Elmer, Jonathan, Moseby-Knappe, Marion, Skrifvars, Markus B., Coppler, Patrick J., Kurtz, Pedro

Mayo Clinic

JAMA Network Open | March 26, 2025 | Volume: 8 | Issue: 3 | Pages: e251714

10.1001/jamanetworkopen.2025.1714 | PMID 40131275 Get It

ImportanceUnderstanding the relationship between patients’ clinical characteristics and outcomes is fundamental to medicine. When critically ill patients die after withdrawal of life-sustaining therapy (WLST), the inability to observe the potential for recovery with continued aggressive care could bias future clinical decisions and research.ObjectiveTo quantify the frequency with which experts consider patients who died after WLST following resuscitated cardiac arrest to have had recovery potential if life-sustaining therapy had been continued.Design, Setting, and ParticipantsThis prospective cohort study included comatose adult patients (aged ≥18 years) treated following resuscitation from cardiac arrest at a single academic medical center between January 1, 2010, and July 31, 2022. Patients with advanced directives limiting critical care or who experienced cardiac arrest of traumatic or neurologic etiology were excluded. An international cohort of experts in post-arrest care based on clinical experience and academic productivity was identified. Experts reviewed the cases between August 24, 2022, and February 11, 2024.ExposurePatients who died after WLST.Main Outcome and MeasuresThree or more experts independently estimated recovery potential for each patient had life-sustaining treatment been continued, using a 7-point numerical ordinal scale. In the primary analysis, which involved the patient cases with death after WLST, a 1% or greater estimated recovery potential was considered to be clinically meaningful. In secondary analyses, thresholds of 5% and 10% estimated recovery probability were explored.ResultsA total of 2391 patients (median [IQR] age, 59 [48-69] years; 1455 men [60.9%]) were included, of whom 714 (29.9%) survived to discharge. Cases of uncertain outcome (1431 patients [59.8%]) in which WLST preceded death were reviewed by 38 experts who rendered 4381 estimates of recovery potential. In 518 cases (36.2%; 95% CI, 33.7%-38.7%), all experts believed that recovery potential was less than 1% if life-sustaining therapies had been continued. In the remaining 913 cases (63.8%; 95% CI, 61.3%-66.3%), at least 1 expert believed that recovery potential was at least 1%. In 227 cases (15.9%; 95% CI, 14.0%-17.9%), all experts agreed that recovery potential was at least 1%, and in 686 cases (47.9%; 95% CI, 45.3%-50.6%), expert estimates differed at this threshold.Conclusions and RelevanceIn this cohort study of comatose patients resuscitated from cardiac arrest, most who died after WLST were considered by experts to have had recovery potential. These findings suggest that novel solutions to avoiding deaths based on biased prognostication or incomplete information are needed.
Histopathologic Features in Vancomycin‐Associated Drug‐Induced Hypersensitivity Syndrome
Haberecht, Hannah, Ziebart, Rachel, Iverson, Olivia , Todd, Austin, Davis, Mark D. P. , Wetter, David A. , Sartori‐Valinotti, Julio C. , McEvoy, Marian T., Aghazadeh, Nessa , Johnson, Emma F. , Haberecht, Hannah B , Ziebart, Rachel L, Iverson, Olivia C, Davis, Mark D., Cantwell, Hafsa M. , Aghazadeh Mohandesi, Nessa , Ziebart, Rachel L , Davis, Mark D.P. , Alavi, Afsáneh

Mayo Clinic

Journal of Cutaneous Pathology | March 25, 2025 | Volume: 52 | Issue: 6 | Pages: 442-451

10.1111/cup.14804 | PMID 40129304 Get It

ABSTRACTBackgroundDrug‐induced hypersensitivity syndrome (DiHS), or drug reaction with eosinophilia and systemic symptoms (DRESS), is a delayed and severe immune response to certain medications. We investigated vancomycin‐induced DiHS/DRESS, notable for frequent and severe organ involvement, to describe its specific histopathology and the correlations between histopathologic and clinical findings.MethodsA retrospective review was conducted to identify patients between 2006 and 2022 who received vancomycin, had archived skin biopsy specimens, and were scored as having probable or definite DiHS/DRESS. Clinical features were retrospectively collected, and biopsy specimens were reviewed by a board‐certified dermatopathologist. A subset of histopathologic and clinical features was analyzed for statistical correlation.ResultsTwenty‐three patients met the inclusion criteria. Most biopsy specimens (87%) showed an eczematous reaction pattern; 17 (74%) showed a secondary reaction pattern. Spongiosis (87%) and neutrophilic infiltration (91%) were common epidermal characteristics. The dermal inflammatory infiltrate was frequently superficial (87%) and consistently included plasma cells (96%). Eosinophils were present in the dermis in 70% of cases. Parakeratosis negatively correlated with liver involvement and positively correlated with desquamative rash. Epidermal lymphocytes were negatively correlated with the RegiSCAR score.ConclusionsVancomycin‐associated DiHS/DRESS histopathology was characterized by a frequent eczematous reaction pattern, multiple coexisting reaction patterns, and epidermal neutrophilic infiltration.
Inside-Out Overview of the Increasing Organ Transplant Access Model
Soliman, Karim , Anand, Prince M. , Perry, Amy , Cheungpasitporn, Wisit , Daoud, Ahmed , Kamal, Ahmed , Fülöp, Tibor , DuBay, Derek A. , Soliman, Karim M , DuBay, Derek , Cheungpasitporn, Wisit , Fülöp, Tibor , Anand, Prince M.

Mayo Clinic

Kidney360 | March 22, 2025 | Volume: 6 | Issue: 5 | Pages: 857-860

10.34067/kid.0000000780 | PMID 40116866 Get It